APPLICATION OF BOTULINUM TOXIN A INJECTION IN PATIENTS WITH UPPER LIMB SPASTICITY
Main Article Content
Abstract
Background: Muscle spasticity is a part of upper motor neuron syndrome that causes deformity, pain and reduced motor function. Botulinum toxin is increasingly used to treat spasticity caused by stroke or traumatic brain injury. Objectives: To evaluate the treatment effectiveness of Bobotulinum toxin A in the treatment of upper limb spasticity at Soc Trang General Hospital in 2024. Materials and methods: A case series of patients with upper limb muscle spasticity was described from July 21, 2023, in which all patients were treated with AbobotulinumtoxinA (BoNT-A) injections. Results: The mean MAS score at 2 weeks post-injection (2.03 ± 0.75) was significantly lower than the pre-injection baseline (2.88 ± 0.82) with p < 0.001. VAS score, Barthel index, and GAS score showed statistically significant improvements at 2, 4, and 12 weeks after injection. None of the patients experienced any side effects after Abobotulinum toxin A injection. Conclusion: Our study demonstrated the effectiveness of Bobotulinum toxin A in improving muscle tone, function, and quality of life.
Keywords
Botulinum toxin A, stroke, function, upper limb
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
References
2. Garces K., et al. Botulinum toxin A for upper and lower limb spasticity : a systematic review. Canadian Coordinating Office for Health Technology Assessment. 2005.
3. Hesse S, et al. Botulinum toxin type A and short-term electrical stimulation in the treatment of upper limb flexor spasticity after stroke: a randomized, double-blind, placebo-controlled trial. Clin Rehabil. 1998. 12(5), 381-8, doi: 10.1191/026921598668275996.
4. Sabrina F., Lisa Z. Modified Ashworth Scale. In: Nicol Korner-Bitensky, Elissa S., editors. 2011.
5. Sung YT, Wu JS. The Visual Analogue Scale for Rating, Ranking and Paired-Comparison (VAS-RRP): A new technique for psychological measurement. Behav Res Methods. 2018. 50(4), 1694-1715. doi: 10.3758/s13428-018-1041-8.
6. Quinn TJ, Langhorne P, Stott DJ. Barthel index for stroke trials: development, properties, and application. Stroke. 2011. 42(4), 1146-51. doi: 10.1161/Stroke AHA.110.598540.
7. Turner-Stokes L. Goal attainment scaling (GAS) in rehabilitation: a practical guide. Clin Rehabil. 2009. 23(4), 362-70. doi: 10.1177/0269215508101742.
8. Nguyễn Thị Thu Huyền, Nguyễn Tuấn Lượng, Vũ Thị Phượng. Bước đầu đánh giá hiệu quả tiêm BTX-A điều trị co cứng cơ sau đột quỵ não tại bệnh viện Hữu nghị Việt Tiệp. Y học thường thức. 2018.
9. Ghroubi S, Alila S, Elleuch W, et al. Efficacy of botulinum toxin A for the treatment of hemiparesis in adults with chronic upper limb spasticity. Pan Afr Med J. 2020. 35, 55. doi: 10.11604/pamj.2020.35.55.16091.
10. Bumbea AM, Rogoveanu OC, et al. Management of Upper-Limb Spasticity Using Modern Rehabilitation Techniques versus Botulinum Toxin Injections Following Stroke. Life (Basel). 2023. 13(11), 2218. doi: 10.3390/life13112218.
11. Wissel J, Fheodoroff K, et al. Effectiveness of AbobotulinumtoxinA in Post-stroke Upper Limb Spasticity in Relation to Timing of Treatment. Front Neurol. 2020. 11, 104. doi: 10.3389/fneur.2020.00104.
12. Turner-Stokes L, et al. Results from the Upper Limb International Spasticity Study-II (ULISII):a large, international, prospective cohort study investigating practice and goal attainment following treatment with botulinum toxin A in real-life clinical management. BMJ Open. 2013. 3(6), e002771. doi: 10.1136/bmjopen-2013-002771.